New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
05:53 EDTGILD, AZNStocks with implied volatility movement; GILD AZN
Stocks with implied volatility movement; Gilead (GILD) 34, AstraZeneca (AZN) 27 according to iVolatility.
News For GILD;AZN From The Last 14 Days
Check below for free stories on GILD;AZN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 23, 2014
16:13 EDTGILDGilead raises FY14 net product sales guidance to $21B-$23B from $11.3B-$11.5B
Subscribe for More Information
16:09 EDTGILDGilead reports Q2 product revenue $6.41B vs. $2.66B last year
Reports Q2 Royalty, contract, and other revenues $122M vs. 110.1M last year. John C. Martin, PhD, Gilead’s chairman and CEO stated, “During Q2, Gilead continued to make significant progress led by strong Sovaldi sales. Since December’s launch, Sovaldi has been prescribed for more than 80,000 patients in the U.S. and Europe, underscoring the medical community’s recognition of the benefits of this product. We look forward to making Sovaldi available in additional countries.”
16:05 EDTGILDGilead reports Q2 EPS $2.36, consensus $1.79
Subscribe for More Information
16:01 EDTGILDGilead trading halted, pending news
Subscribe for More Information
16:00 EDTGILDOptions Update; July 23, 2014
iPath S&P 500 VIX Short-Term Futures up 23c to 28.17. Option volume leaders: AAPL FB C GILD MSFT PBR NFLX AMZN TWTR TSLA according to Track Data
15:43 EDTGILDGilead July weekly 90 straddle priced for 5.5% move into Q2
Subscribe for More Information
15:30 EDTGILDNotable companies reporting after market close
Subscribe for More Information
11:40 EDTGILDFDA approves Zydelig for three types of blood cancers
Subscribe for More Information
July 22, 2014
06:14 EDTGILDGilead July weekly volatility elevated into Q2
Subscribe for More Information
05:25 EDTAZNAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
July 21, 2014
16:00 EDTGILDOptions Update; July 21, 2014
iPath S&P 500 VIX Short-Term Futures up 65c to 28.53. Option volume leaders: AAPL FB NFLX DG CMCSA GILD PBR TWTR TSLA according to Track Data.
09:38 EDTGILDActive equity options trading on open
Subscribe for More Information
07:21 EDTGILDGilead could be hurt by new HCV drugs, says Wells Fargo
Noting that data on a new Merck (MRK) HCV treatment is expected in November, Wells Fargo thinks Merck's HCV drug could be combined with Gilead's (GILD) Sovaldi to shorten the duration of treatment to four weeks. Other companies could take similar actions, and Gilead's per patient revenues would be significantly reduced if this occurs, the firm warned. However, it continues to have an upbeat outlook on Gilead heading into what it sees as a strong quarter and is still upbeat on the company's long-term HCV opportunity. It keeps an Outperform rating on Gilead.
06:43 EDTGILDGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
12:46 EDTGILDGilead drug cocktail helps treat HIV/HCV-coinfected patients, JAMA says
Subscribe for More Information
July 16, 2014
11:57 EDTGILDStocks with call strike movement; GILD YHOO
Subscribe for More Information
10:36 EDTAZNTreasury calls on Congress to halt inversion deals
Subscribe for More Information
08:01 EDTAZNAlexion names former AstraZeneca CEO David Brennan to board
Subscribe for More Information
07:59 EDTAZNTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
July 14, 2014
09:28 EDTGILDCentene best positioned Medicaid pure play to post Q2 EPS beat, says Sterne Agee
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use